Next Article in Journal
Self-Sampling for Cervical Cancer Screening: Empowering Women to Lead a Paradigm Change in Cancer Control
Previous Article in Journal
Updates from the 2017 American Society of Hematology Annual Meeting: Practice-Changing Studies in Relapsed and Refractory Mantle Cell Lymphoma
 
 
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Meeting Report

Updates from the 2017 American Society of Hematology Annual Meeting: Practice-Changing Studies in Untreated Chronic Lymphocytic Leukemia

1
Division of Hematology and Hematological Malignancies, University of Calgary and Foothills Medical Centre, Calgary, AB, Canada
2
Leukemia/Bone Marrow Transplant Program of British Columbia, University of British Columbia, Division of Hematology, Vancouver General Hospital, and Division of Hematology, BC Cancer Agency, Vancouver, BC, Canada
3
Impact Medicom Inc., Toronto, ON M6S 3K2, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2018, 25(1), 91-103; https://doi.org/10.3747/co.25.4005
Submission received: 2 November 2017 / Revised: 3 December 2017 / Accepted: 6 January 2018 / Published: 1 February 2018

Abstract

The 2017 annual meeting of the American Society of Hematology took place 9–12 December in Atlanta, Georgia. At the meeting, the oral presentations included results from key studies on the first-line treatment of chronic lymphocytic leukemia. A series of phase ii studies focusing on the efficacy and safety of novel treatment strategies were especially notable. One concerned the health-related quality of life results from the gibb study, which had examined the combination of obinutuzumab and bendamustine. A second evaluated the venetoclax–ibrutinib regimen in patients with high-risk disease. The third assessed the combination of ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab in patients with mutated immunoglobulin heavy-chain variable region genes. The fourth examined the combination of ibrutinib, fludarabine, cyclophosphamide, and rituximab in younger patients. And the final study evaluated obinutuzumab–ibrutinib followed by a minimal residual disease strategy in fit patients. Our meeting report describes the foregoing studies and presents interviews with investigators and commentaries by Canadian hematologists about the potential effects on Canadian practice.
Keywords: untreated disease; first-line treatments; treatment-naïve patients; chronic lymphocytic leukemia untreated disease; first-line treatments; treatment-naïve patients; chronic lymphocytic leukemia

Share and Cite

MDPI and ACS Style

Owen, C.; Toze, C.; Christofides, A. Updates from the 2017 American Society of Hematology Annual Meeting: Practice-Changing Studies in Untreated Chronic Lymphocytic Leukemia. Curr. Oncol. 2018, 25, 91-103. https://doi.org/10.3747/co.25.4005

AMA Style

Owen C, Toze C, Christofides A. Updates from the 2017 American Society of Hematology Annual Meeting: Practice-Changing Studies in Untreated Chronic Lymphocytic Leukemia. Current Oncology. 2018; 25(1):91-103. https://doi.org/10.3747/co.25.4005

Chicago/Turabian Style

Owen, C., C. Toze, and A. Christofides. 2018. "Updates from the 2017 American Society of Hematology Annual Meeting: Practice-Changing Studies in Untreated Chronic Lymphocytic Leukemia" Current Oncology 25, no. 1: 91-103. https://doi.org/10.3747/co.25.4005

Article Metrics

Back to TopTop